Literature DB >> 18515525

Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.

Ji Hyae Lim1, Shin Young Kim, So Yeon Park, Jae Hyug Yang, Moon Young Kim, Hyun Mee Ryu.   

Abstract

OBJECTIVE: Imbalance between angiogenesis-related factors is closely related to the development of preeclampsia. The objective was to estimate the most effective and accurate predictive biomarker among levels and ratios of angiogenesis-related factors, including soluble fms-like tyrosine kinase 1 (sFlt-1), soluble endoglin, placental growth factor (PlGF), and transforming growth factor-beta1 (TGF-beta1), in women who subsequently developed preeclampsia.
METHODS: A nested cohort study was conducted to estimate the levels of sFlt-1, soluble endoglin, PlGF, and TGF-beta1 in plasma collected in the second trimester from 40 women who subsequently developed preeclampsia and 100 contemporaneous normotensive women.
RESULTS: Levels of sFlt-1 and soluble endoglin were significantly higher in women with preeclampsia than in normotensive women, whereas levels of PlGF and TGF-beta1 were lower (P<.001). In women with preeclampsia, sFlt-1/PlGF, soluble endoglin/TGF-beta1, and the combined ratio of (sFlt-1+soluble endoglin)/(PlGF+TGF-beta1) were significantly higher than in normotensive women (P<.001) and even greater in severe preeclampsia with preterm delivery compared with mild preeclampsia with term delivery (P<.05). At equivalent sensitivity (85%), the false-positive rate was 45% for sFlt-1, 41% for soluble endoglin, 33% for sFlt-1/PlGF, 21% for soluble endoglin/TGF-beta1, and 10% for the combined ratio. After adjusting for potential confounding factors, the risks for developing preeclampsia were as follows: odds ratio (OR) 6.9 [95% confidence interval 2.3-20.7] for sFlt-1 level, 7.1 [2.3-21.7] for soluble endoglin level, 6.8 [2.4-19.4] for sFlt-1/PlGF, 38.8 [9.8-154.3] for soluble endoglin/TGF-beta1, and 74.8 [17.6-316.7] for the combined ratio.
CONCLUSION: The combined ratio of angiogenesis-related factors showed the lowest false-positive rate and the highest OR for prediction of preeclampsia, indicating that it may provide more effective prediction of development of preeclampsia. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515525     DOI: 10.1097/AOG.0b013e3181719b7a

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  33 in total

1.  Association between genetic polymorphisms in androgen receptor gene and the risk of preeclampsia in Korean women.

Authors:  Ji Hyae Lim; Shinyoung Kim; Si Won Lee; So Yeon Park; Jung Yeol Han; Jin Hoon Chung; Moon Young Kim; Jae Hyug Yang; Hyun Mee Ryu
Journal:  J Assist Reprod Genet       Date:  2010-10-05       Impact factor: 3.412

2.  Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia.

Authors:  Ossama M Reslan; Raouf A Khalil
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2010-10-01

3.  Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?

Authors:  Robert W Powers; James M Roberts; Daniel A Plymire; Dominick Pucci; Saul A Datwyler; Don M Laird; David C Sogin; Arun Jeyabalan; Carl A Hubel; Robin E Gandley
Journal:  Hypertension       Date:  2012-05-29       Impact factor: 10.190

Review 4.  Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy.

Authors:  Sajjadh M J Ali; Raouf A Khalil
Journal:  Expert Opin Ther Targets       Date:  2015-08-17       Impact factor: 6.902

5.  Midterm eGFR and Adverse Pregnancy Outcomes: The Clinical Significance of Gestational Hyperfiltration.

Authors:  Sehoon Park; Seung Mi Lee; Joong Shin Park; Joon-Seok Hong; Ho Jun Chin; Ki Young Na; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Hajeong Lee
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-13       Impact factor: 8.237

6.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

7.  A fetal variant in the GCM1 gene is associated with pregnancy induced hypertension in a predominantly hispanic population.

Authors:  Melissa L Wilson; Doerthe Brueggmann; Daniel H Desmond; John E Mandeville; T Murphy Goodwin; Sue Ann Ingles
Journal:  Int J Mol Epidemiol Genet       Date:  2011-05-05

Review 8.  Anti-angiogenesis and Preeclampsia in 2016.

Authors:  Susanne Schrey-Petersen; Holger Stepan
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

9.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

10.  Combination of serum angiopoietin-2 and uterine artery Doppler for prediction of preeclampsia.

Authors:  Ploynin Puttapitakpong; Vorapong Phupong
Journal:  Hypertens Res       Date:  2015-10-22       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.